MIAMI, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ:VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast
Beam Therapeutics Inc (NASDAQ:BEAM) announced new preclinical data demonstrating the potential of its multiplex base editing approach to reduce hepatitis B…
Pfizer Inc (NYSE:PFE) announced positive topline results from its European Phase 3 study in infants evaluating its 20-valent pneumococcal conjugate vaccine…
The European Commission approved Roche Holding AG’s (OTC:RHHBY) Vabysmo (faricimab) for neovascular or ‘wet’ age-related macular degeneration (nAMD) and visual impairment…
The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending approval of AbbVie Inc’s (NYSE:ABBV)…
Virios Therapeutics Inc’s (NASDAQ:VIRI) shares crashed after its FORTRESS Phase 2b trial of IMC-1 antiviral combination therapy for fibromyalgia failed…
CAMBRIDGE, Mass., Sept. 19, 2022 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced the
EMPOWER CAD is the First Prospective, Female-Only Study of Coronary Interventions
Study Seeks to Confirm Benefits of Shockwave's Coronary IVL in Females Who Historically Have Suffered Less